Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease
Open accessAbstract
Retinoic acid (RA) plays an important role in the commitment, maturation and survival of neural cells. Recently, RA was pointed as a therapeutic option for some neurodegenerative diseases, including Parkinson's disease (PD). The administration of RA has been defying, and in this sense we have previously developed novel RA-loaded polymeric nanoparticles (RA-NPs) that ensure the efficient intracellular transport and controlled release of RA. Herein, we show that nanoformulation as an efficient neuroprotective effect on dopaminergic (DA) neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced mouse model for PD. The results showed that the RA-NPs administration induced a significant reduction of DA neuron loss in the substantia nigra (SN) as well as their neuronal fiber/axonal innervations in the striatum. Furthermore, we observed an increase in the expression levels of the transcription factors Pitx3 and Nurr1 induced by RA-NPs, showing its supportive effect on the development and functional maintenance of DA neurons in PD. This is the first study showing that RA-NPs can be an innovative strategy to halt the progression of PD pathogenesis, suggesting that this nanoformulation could be of particular interest for the development of new approaches for PD therapeutics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Stereotaxic injection of ATRA-containing nanoparticles in the striatum protected nigral dopaminergic neurons in an in vivo PD model.
“Stereotaxic injection of ATRA-containing nanoparticles in the striatum protected nigral dopaminergic neurons in an in vivo PD model68.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [68]
RA-containing nanoparticles increased expression of Nurr1 and Pitx3, key regulators of dopaminergic neuronal development and maintenance.
“RA-containing nanoparticles increased expression of Nurr1 and Pitx3, key regulators of dopaminergic neuronal development and maintenance68,88.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · see citing works
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859 · see citing works
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · see citing works
Sensors and regulators of intracellular pH
Casey, J. R., Grinstein, S., & Orlowski, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2820 · Cited by 2,276 · see citing works
Retinoic acid in the development, regeneration and maintenance of the nervous system
Maden, M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2212 · Cited by 896 · see citing works
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 859 · see citing works
Nuclear retinoid receptors and the transcription of retinoid-target genes
Bastien, J., & Rochette-Egly, C. (2004) · Gene · doi:10.1016/j.gene.2003.12.005 · Cited by 773 · see citing works
The acute and chronic toxic effects of vitamin A
Penniston, K. L., & Tanumihardjo, S. A. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.191 · Cited by 576 · see citing works
Kastner, P., Mark, M. P., Ghyselinck, N. B., Krężel, W., Dupé, V., Grondona, J. M., & Chambon, P. (1997) · Development · doi:10.1242/dev.124.2.313 · Cited by 429 · see citing works
Blasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374 · see citing works
Smidt, M. P., van Schaick, H. S. A., Lanctôt, C., Tremblay, J., Cox, J. J., van der Kleij, A. A. M., Wolterink, G., Drouin, J., & Burbach, J. P. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13305 · Cited by 363 · see citing works
Zetterström, R. H., Williams, R., Perlmann, T., & Olson, L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00074-5 · Cited by 340 · see citing works
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
Jankovic, J., Chen, S., & Le, W. D. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.09.001 · Cited by 325 · see citing works
High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system.
McCaffery, P., & Dräger, U. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7772 · Cited by 266 · see citing works
Solubility of retinoids in water
Szuts, E. Z., & Harosi, F. I. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90482-x · Cited by 223 · see citing works
Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigra
Chu, Y., Kompoliti, K., Cochran, E. J., Mufson, E. J., & Kordower, J. H. (2002) · The Journal of Comparative Neurology · doi:10.1002/cne.10261 · Cited by 201 · see citing works
Smits, S. M., Ponnio, T., Conneely, O. M., Burbach, J. P. H., & Smidt, M. P. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02885.x · Cited by 194 · see citing works
Galter, D., Buervenich, S., Belin, A. C., Anvret, M., & Olson, L. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.001 · Cited by 175 · see citing works
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.12.010 · Cited by 150 · see citing works
Gibrat, C., Saint‐Pierre, M., Bousquet, M., Lévesque, D., Rouillard, C., & Cicchetti, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06072.x · Cited by 136 · see citing works
9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes
Xu, J., & Drew, P. D. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.004 · Cited by 124 · see citing works
Maia, J., Santos, T., Aday, S., Agasse, F., Cortes, L., Malva, J. O., Bernardino, L., & Ferreira, L. (2011) · ACS Nano · doi:10.1021/nn101724r · Cited by 99 · see citing works
Self-citationSantos, T., Ferreira, R., Maia, J., Agasse, F., Xapelli, S., Cortes, L., Bragança, J., Malva, J. O., Ferreira, L., & Bernardino, L. (2012) · ACS Nano · doi:10.1021/nn304541h · Cited by 92 · see citing works
Self-citationKatsuki, H., Kurimoto, E., Takemori, S., Kurauchi, Y., Hisatsune, A., Isohama, Y., Izumi, Y., Kume, T., Shudo, K., & Akaike, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06171.x · Cited by 88 · see citing works
Serra, P. A., Sciola, L., Delogu, M. R., Spano, A., Monaco, G., MIELE, E., Rocchitta, G., Miele, M., Migheli, R., & Desole, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202099200 · Cited by 84 · see citing works
Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)
Jarvis, M. F., & Wagner, G. C. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90068-1 · Cited by 79 · see citing works
Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease
Decressac, M., Pain, S., Chabeauti, P.-Y., Frangeul, L., Thiriet, N., Herzog, H., Vergote, J., Chalon, S., Jaber, M., & Gaillard, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.018 · Cited by 76 · see citing works
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease
Grünblatt, E., Zehetmayer, S., Jacob, C., Müller, T., Jost, W. H., & Riederer, P. F. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0509-1 · Cited by 66 · see citing works
Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s disease
Liu, H., Wei, L., Tao, Q., Deng, H., Ming, M., Xu, P., & Le, W. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03644.x · Cited by 60 · see citing works
Goulart, G. A. C., Oréfice, R. L., Vilela, J. M. C., Andrade, M. S., & Ferreira, L. A. M. (2007) · Journal of Microencapsulation · doi:10.1080/02652040701288519 · Cited by 55 · see citing works
Self-citationLuk, K. C., Rymar, V. V., van den Munckhof, P., Nicolau, S., Steriade, C., Bifsha, P., Drouin, J., & Sadikot, A. F. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12160 · Cited by 55 · see citing works
Narvekar, M., Xue, H. Y., & Wong, H. L. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.042 · Cited by 52 · see citing works
Buervenich, S., Belin, A. C., Galter, D., Shahabi, H. N., Johnels, B., Holmberg, B., Ahlberg, J., Nissbrandt, H., Eerola, J., Hellström, O., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.74 · Cited by 51 · see citing works
Thang, S. H., Kobayashi, M., & Matsuoka, I. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02917.2000 · Cited by 48 · see citing works
Kong, X., Cai, Z., Pan, L., Zhang, L., Shu, J., Dong, Y., Yang, N., Li, Q., Huang, X., & Zuo, P. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.040 · Cited by 48 · see citing works
Yin, L.-H., Shen, H., Dı́az-Ruiz, O., Bäckman, C. M., Bae, E. C., Yu, S., & Wang, Y. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-120 · Cited by 47 · see citing works
Rojas, P., Ruiz-Sánchez, E., Rojas, C., & Ögren, S. O. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.004 · Cited by 41 · see citing works
Peng, J., & Andersen, J. K. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00656.x · Cited by 37 · see citing works
Retinoic acid signaling in axonal regeneration
Puttagunta, R., & Giovanni, S. D. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00059 · Cited by 37 · see citing works
PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine
Regnier-Delplace, C., Boullay, O. T. D., Siepmann, F., Martín-Vaca, B. M., Degrave, N., Demonchaux, P., Jentzer, O., Bourissou, D., & Siepmann, J. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.008 · Cited by 35 · see citing works
Suzuki, H., Ono, K., & Sawada, M. (2014) · Journal of neural transmission · doi:10.1007/s00702-014-1209-z · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 541 · see citing works
Neuroprotective Effect of Antioxidants in the Brain
Lee, K. H., Cha, M., & Lee, B. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197152 · Cited by 527 · see citing works
Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives
Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B. H., & Anjum, I. (2021) · Pharmaceuticals · doi:10.3390/ph14080707 · Cited by 249 · see citing works
Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders
Moradi, S. Z., Momtaz, S., Bayrami, Z., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00238 · Cited by 181 · see citing works
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138 · see citing works
Self-citationNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
The Role of Vitamins in Neurodegenerative Disease: An Update
Nand, S., Singh, P., Steinbusch, H. W. M., Vamanu, E., Ashraf, G. M., & Singh, M. P. (2021) · Biomedicines · doi:10.3390/biomedicines9101284 · Cited by 126 · see citing works
Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation
Rocha, S. M., Saraiva, T., Cristóvão, A. C., Ferreira, R., Santos, T., Esteves, M., Saraiva, C., Je, G., Cortes, L., Valero, J., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0600-0 · Cited by 117 · see citing works
Self-citationNurr1‐Based Therapies for Parkinson's Disease
Dong, J., Li, S., Mo, J., Cai, H., & Le, W. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12536 · Cited by 115 · see citing works
Jakaria, M., Haque, M. E., Cho, D.-Y., Azam, S., Kim, I., & Choi, D. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1487-4 · Cited by 109 · see citing works
Bellanthudawa, B. K. A., Nawalage, N. M. S. K., Handapangoda, H. M. A. K., Suvendran, S., Wijayasenarathne, K. A. S. H., Rathnasuriya, M. L. D., Wickramasinghe, P. G. M. U., Aberathna, A. A. A. U., Tennakoon, A., & Perera, I. J. J. U. N. (2023) · Nanotechnology for Environmental Engineering · doi:10.1007/s41204-023-00344-7 · Cited by 99 · see citing works
Micro- and nanotechnology approaches to improve Parkinson's disease therapy
Torres-Ortega, P. V., Saludas, L., Hanafy, A. S., Garbayo, E., & Blanco‐Prieto, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.036 · Cited by 83 · see citing works
Dual role of histamine on microglia-induced neurodegeneration
Barata‐Antunes, S., Cristóvão, A. C., Pires, J. P., Rocha, S. M., & Bernardino, L. I. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.12.016 · Cited by 73 · see citing works
Self-citationThe substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration
Fu, Y., Paxinos, G., WATSON, C. R. R., & Halliday, G. M. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.02.001 · Cited by 66 · see citing works
Carradori, D., Eyer, J., Saulnier, P., Véronique Préat, A., & Rieux, A. D. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.032 · Cited by 63 · see citing works
Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation
Moutinho, M., Codocedo, J. F., Puntambekar, S. S., & Landreth, G. E. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021807 · Cited by 55 · see citing works
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease
Marie, A., Darricau, M., Touyarot, K., Parr‐Brownlie, L. C., & Bosch‐Bouju, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212671 · Cited by 54 · see citing works
Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems
Rodríguez‐Nogales, C., Garbayo, E., Carmona‐Abellán, M., Luquín, M. R., & Blanco‐Prieto, M. J. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.11.009 · Cited by 54 · see citing works
The role of NURR1 in metabolic abnormalities of Parkinson’s disease
Al‐Nusaif, M., Yang, Y., Li, S., Cheng, C., & Le, W. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00544-w · Cited by 52 · see citing works
Anti-Inflammatory Strategy for M2 Microglial Polarization Using Retinoic Acid-Loaded Nanoparticles
Machado‐Pereira, M., Santos, T., Ferreira, L., Bernardino, L. I., & Ferreira, R. (2017) · Mediators of Inflammation · doi:10.1155/2017/6742427 · Cited by 52 · see citing works
Self-citationPhysiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. R., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2021) · Advanced Science · doi:10.1002/advs.202002085 · Cited by 51 · see citing works
Küçükdoğru, R., Türkez, H., Arslan, M. E., Tozlu, Ö. Ö., Sönmez, E., Mardinoğlu, A., Cacciatore, I., & Stefano, A. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00559-6 · Cited by 51 · see citing works
Medina, D. X., Chung, E. P., Teague, C. D., Bowser, R. P., & Sirianni, R. W. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00224 · Cited by 47 · see citing works
Neuroprotective effect of phytoconstituents via nanotechnology for treatment of Alzheimer diseases
Paramanick, D., Singh, V. D., & Singh, V. K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.058 · Cited by 47 · see citing works
A nanoformulation for the preferential accumulation in adult neurogenic niches
Praça, C., Rai, A., Santos, T., Cristóvão, A. C., Pinho, S. L. C., Cecchelli, R., Dehouck, M., Bernardino, L. I., & Ferreira, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.013 · Cited by 46 · see citing works
Self-citationLimegrover, C. S., Yurko, R., Izzo, N. J., Mozzoni, K., Rehak, C., Look, G. C., Rishton, G. M., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24782 · Cited by 42 · see citing works
Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
Behl, T., Kaur, D., Sehgal, A., Singla, R. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Meraya, A. M., & BUNGAU, S. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976799 · Cited by 42 · see citing works
Bandiwadekar, A., Jose, J., Khayatkashani, M., Habtemariam, S., Kashani, H. R. K., & Nabavi, S. M. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01922-7 · Cited by 42 · see citing works
Repositioning drugs by targeting network modules: a Parkinson’s disease case study
Yue, Z., Arora, I., Zhang, E. Y., Laufer, V. A., Bridges, S. L., & Chen, J. Y. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1889-0 · Cited by 40 · see citing works
Hummel, R., Ulbrich, S., Appel, D., Li, S., Hirnet, T., Zander, S., Bobkiewicz, W., Gölz, C., & Schäfer, M. K. E. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15259 · Cited by 38 · see citing works
The Crucial Involvement of Retinoid X Receptors in DDE Neurotoxicity
Wnuk, A., Rzemieniec, J., Litwa, E., Lasoń, W., Krzeptowski, W., Wójtowicz, A. K., & Kajta, M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9572-6 · Cited by 34 · see citing works
Gupta, A., & Singh, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02646-w · Cited by 34 · see citing works
Nanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases
Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 34 · see citing works
Sim, Y., Park, G., Eo, H., Huh, E., Gu, P. S., Hong, S.-P., Pak, Y. K., & Oh, M. S. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.10.029 · Cited by 33 · see citing works
Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease
Al‐Nusaif, M., Lin, Y., Li, T., Cheng, C., & Le, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416184 · Cited by 31 · see citing works
DeRidder, L. B., Sharma, A., Liaw, K., Sharma, R. B., John, J., Kannan, S., & Kannan, R. M. (2020) · Nanoscale · doi:10.1039/d0nr05958g · Cited by 31 · see citing works
Retinoic acid receptor-targeted drugs in neurodegenerative disease
Clark, J. N., Whiting, A., & McCaffery, P. J. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1811232 · Cited by 30 · see citing works
Wang, T., Peng, Q., Liu, B., Liu, Y., & Wang, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00418 · Cited by 27 · see citing works
Effect of retinoic acid on the neurovascular unit: A review
Pouso, M. R., & Cairrão, E. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.03.011 · Cited by 27 · see citing works
Farshbaf, M. J., Forouzanfar, M., Ghaedi, K., Kiani‐Esfahani, A., Peymani, M., Nejati, A. S., Izadi, T., Karbalaie, K., Noorbakhshnia, M., Rahgozar, S., et al. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2764-4 · Cited by 24 · see citing works
Nanoparticle enhanced blue light therapy
Akasov, R., Khaydukov, E. V., Yamada, M., Zvyagin, A. V., Leelahavanichkul, A., Leanse, L. G., Dai, T., & Prow, T. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114198 · Cited by 23 · see citing works
Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes
Guo, S., & Yi, C. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0158 · Cited by 22 · see citing works
Retinoic acid in Parkinson's disease: Molecular insights, therapeutic advances, and future prospects
Pareek, A., Singhal, R., Pareek, A., Ghazi, T., Kapoor, D. U., Ratan, Y., Singh, A. K., Jain, V., & Chuturgoon, A. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123010 · Cited by 21 · see citing works
Nguyen, T.-V., Khanal, S., Lee, E.-H., Choi, J., Bohara, G., Rimal, N., Choi, D., & Park, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03104-8 · Cited by 20 · see citing works
Yan, T., Yuan, M., Nguyen, N., Chen, J., Feng, X., Fan, T., Harnett, M. C., Xiao, Z., Li, Y., Pellois, J., et al. (2023) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-023-00811-4 · Cited by 20 · see citing works
Kanojia, N., Thapa, K., Kaur, G., Sharma, A., Puri, V., & Verma, N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104074 · Cited by 19 · see citing works
Vassal, M., Martins, F., Monteiro, B., Tambaro, S., Martínez‐Murillo, R., & Rebelo, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04246-w · Cited by 22 · see citing works
Medina, D. X., Chung, E. P., Bowser, R. P., & Sirianni, R. W. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.013 · Cited by 19 · see citing works
Marie, A., Leroy, J., Darricau, M., Alfos, S., Smedt, V. D., Richard, E., Vancassel, S., & Bosch‐Bouju, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.811843 · Cited by 17 · see citing works
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
Wang, Z., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1907 · Cited by 18 · see citing works
Duprey‐Díaz, M. V., Blagburn, J. M., & Blanco, R. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162626 · Cited by 16 · see citing works
Yuan, M., Yan, T., Li, J., Xiao, Z., Fang, Y., Wang, Y., Zhou, H.-C. “., & Pellois, J. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102392 · Cited by 15 · see citing works
Kang, J.-B., Shah, M.-A., Park, D.-J., & Koh, P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303213 · Cited by 14 · see citing works
Yuan, M., Harnett, M. C., Yan, T., Georgas, E., Qin, Y., Zhou, H.-C. “., & Wang, Y. (2022) · Nanomaterials · doi:10.3390/nano12132242 · Cited by 12 · see citing works
Chakraborty, P., Bhattacharyya, C., Sahu, R., Dua, T. K., Kandimalla, R. J. L., & Dewanjee, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105267 · Cited by 11 · see citing works
Possible Roles of Epigenetics in Stem Cell Therapy for Parkinson’s Disease
Thompson, C., Otero, P., Srinageshwar, B., Petersen, R. B., Dunbar, G. L., & Rossignol, J. (2020) · Epigenomics · doi:10.2217/epi-2019-0347 · Cited by 12 · see citing works
Sierri, G., Patrucco, M., Ferrario, D. L., Renda, A., Comi, S., Ciprandi, M., Fontanini, V., Sica, F. S., Sesana, S., Verdugo, M. C., et al. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1991 · Cited by 10 · see citing works
Applications of nanotechnology in nutrition: potential and safety issues
Kulkarni, A. S., Ghugre, P. S., & Udipi, S. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804308-0.00015-7 · Cited by 9 · see citing works
Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases
Nguyen‐Thi, P., Ho, T.-T., Nguyen, T. T., & Vo, G. V. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230707113405 · Cited by 8 · see citing works
Mihajlović, K., Malod‐Dognin, N., Ameli, C., Skupin, A., & Pržulj, N. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae012 · Cited by 7 · see citing works
Bioactive Compound‐Fortified Nanocarriers in the Management of Neurodegenerative Disease: A Review
Singh, A., Maheshwari, S., Yadav, J. P., Kumar, R. K., Verma, A., Singh, S. K., & Prajapati, B. G. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402018 · Cited by 7 · see citing works
Saraiva, C., Lopes‐Nunes, J., Esteves, M., Santos, T., Vale, A. M., Cristóvão, A. C., Ferreira, R., & Bernardino, L. I. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03331-w · Cited by 6 · see citing works
Self-citationChallenges and opportunities in nanotherapeutics targeted for central nervous system disorders
Yong, J. M., Hakobyan, K., Mahmud, S. A. Z., Johnson, D., Lee, J., Diwan, A. D., Gu, Z., Moalem‐Taylor, G., & Mao, G. (2025) · Nanoscale · doi:10.1039/d5nr02463c · Cited by 5 · see citing works
Jiang, P., Wang, J., Wang, X., Zou, L., Wu, D., Xu, Q., Jiang, Y., Yao, M., Hong, Q., & Chi, X. (2025) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2025.1564694 · Cited by 5 · see citing works
Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
Paccione, N., Rahmani, M., Barcia, E., & Negro, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010013 · Cited by 5 · see citing works
Nanobiotechnology in Parkinson’s Disease
Torres-Ortega, P. V., Martínez-Valbuena, I., Martí‐Andrés, G., Hanafy, A. S., Luquin, M. R., Garbayo, E., & Blanco‐Prieto, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_7 · Cited by 4 · see citing works
Tissue localization of retinoic acid receptor (RAR) active drugs
Kouchmeshky, A., Goodman, T. H., Whiting, A., & McCaffery, P. J. A. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.03.012 · Cited by 4 · see citing works
Biomaterials and Stem Cells as Drug/Gene-Delivery Vehicles for Parkinson’s Treatment: An Update
Roshani, M., Kiaie, N., & Aghdam, R. M. (2021) · Regenerative Medicine · doi:10.2217/rme-2021-0050 · Cited by 4 · see citing works
Advanced Polymeric Nanoparticles for the Treatment of Neurodegenerative Diseases
Ferrão, R., & Rai, A. (2024) · Wiley eBooks · doi:10.1002/9783527837021.ch27 · Cited by 3 · see citing works
Ture, N., Desai, D., & Shende, P. K. (2021) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-021-06571-1 · Cited by 2 · see citing works
From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson’s Disease Therapies
Barathan, M., & Abdullah, N. A. H. (2025) · Biology · doi:10.3390/biology14101349 · Cited by 2 · see citing works
Advances in Nanotechnology for Targeted Drug Delivery in Alzheimer's Disease
Maheshwari, S., Kumar, P., Dwivedi, V., Mishra, A., Singh, V. K., & Singh, A. V. (2025) · Current Aging Science · doi:10.2174/0118746098359258250727103551 · Cited by 2 · see citing works
Molecular Targets for Improvement of Parkinson's Disease Therapy
Cocco, T., & Papa, S. (2015) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000173 · Cited by 2 · see citing works
Case Report: A Case of a Patient with Smith–Magenis Syndrome and Early-Onset Parkinson’s Disease
Stern, T., Hussein, Y., Cordeiro, D., Sadis, H., Garin-Shkolnik, T., Spiegel, R., Cohen, S., Harari, R., Schlesinger, I., & Stern, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158447 · Cited by 2 · see citing works
Chasovskikh, N. Y., Grechishnikova, A. Y., & Smirnov, D. V. (2020) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2020-1-108-113 · Cited by 1 · see citing works
Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead
Devi, N., Dhiman, S., Dora, C. P., Singh, T. G., & Awasthi, A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03234-0 · Cited by 1 · see citing works
Sarkar, R., Banu, A. N., Raut, A. M., & Assouguem, A. (2025) · CABI Reviews · doi:10.1079/cabireviews.2025.0070 · Cited by 1 · see citing works
Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease
Bao, Z., Zhi, S., & Jie, M. (2026) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70197 · Cited by 1 · see citing works
Singh, M., & Jindal, D. (2023) · Lecture notes in mechanical engineering · doi:10.1007/978-981-99-3386-0_6 · Cited by 1 · see citing works
Introductory Chapter: Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
Bosch‐Bouju, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89349 · Cited by 1 · see citing works
Nanoformulations for Therapeutics
Rao, P., & Stang, C. R. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-63633-7_6
Obulesu, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819882-7.00002-7
Possible Roles of Epigenetics in Stem Cell Therapy for Parkinson’s Disease
Krubaa, P. (2024) · SBV Journal of Basic Clinical and Applied Health Science · doi:10.4103/sbvj.sbvj_13_24
Dendrimers: Advancing Therapeutic Strategies for Dementia
Singh, A., Maheshwari, S., Ansari, V. A., Verma, A., Mahmood, T., Akhtar, J., Ahsan, F., Vishwakarma, V. K., & Wasim, R. (2025) · Current Aging Science · doi:10.2174/0118746098343913250818112618
Kouchmeshky, A., & McCaffery, P. J. A. (2026) · Advances in biochemistry in health and disease · doi:10.1007/978-3-032-14441-6_15
All-trans retinoic acid and vitamin A in neurodegeneration: from oncology to neuroprotection
Guan, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-22305-1.00013-8
Harbert, D. H. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1806505
Ao, C., Liu, H., Ban, R., Huang, T., Xiao, Y., Chen, W., Feng, Y., Zhao, H., Ban, J., & Li, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1883748
- Authors
- Esteves, M., Cristóvão, A. C., Saraiva, T., Rocha, S. M., Baltazar, G., Ferreira, L., & Bernardino, L.
- Affiliations
- University of Beira Interior (PT)
- Biocant – Associação de Transferência de Tecnologia (PT)
- Corresponding author
- Bernardino, Liliana
- ORCID
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-03-06
- Volume
- 7
- Pages
- 20-20
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC4351630
- OpenAlex
- W2036275831
- Cited by
- 88
- References
- 41
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 8 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 13 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 7 · 2015: 3
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- L'Oreal USA
- Fundação para a Ciência e a Tecnologia (CENTRO-07-ST24-FEDER-002008, COMPETE, SFRH/BPD/69643/2010, PEst-C/SAU/UI0709/2011, EXPL/BIM-MED/0822/2013)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- retinoic acid, polymeric nanoparticles, Parkinson's disease, neuroprotection, dopaminergic neurons, MPTP mouse model, substantia nigra, Pitx3, Nurr1, controlled drug release, nanoformulations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
